Archive for March, 2021
- Increased nuclear power projects fueling rising demand for uranium
- UEC controls one of the largest historical uranium exploration and development databases in United States
- UEC property portfolio includes properties previously explored and developed by senior energy firms
- UEC has fully licensed, low cost, ISR projects positioned to supply the U.S. Uranium Reserve
- Nuclear energy included in Democratic Party’s energy platform for first time in 48 years
After spending a solid ten years in a downward trend, uranium stocks are now making fresh 52-week highs amid increased demand for energy (https://ibn.fm/GXF7e). Uranium Energy (NYSE American: UEC), a U.S.-based uranium mining and exploration company that controls one of the largest historical uranium exploration and development databases in the United States, is positioned to benefit from the trend after having acquired multiple mining sites in North and South America that allow the company to target specific uranium-rich areas.
Increased global demand for nuclear energy continues to drive the demand for uranium while long-term supplies are becoming less certain. Analyst Lyn Alden Schwartzer of Seeking Alpha predicts robust and increasing demand for uranium from developing nations and manufacturing powerhouses like China that continue to increase nuclear power consumption (https://ibn.fm/EI3BY). With lead times for new production spanning between seven to ten years or longer, current prices are not yet at levels that incentivize future production, further exacerbating longer-term supply concerns. Despite these conditions, uranium’s spot price is currently less than its production cost for most Western producers, signaling potential opportunities for suppliers and investors.
UEC controls one of the largest historical uranium exploration and development databases in the United States with properties in various locations, including Texas, New Mexico, Colorado, Arizona and Wyoming. The company’s use of historical exploration data has enabled it to target and acquire properties that have already been explored and developed by senior energy firms in the past, in some cases spending as much as $50 million to develop individual projects.
Since inception in 2005, UEC’s main strategic focus has been on acquiring and developing U.S. in-situ recovery (“ISR”) projects that are an environmentally friendly and lower-cost alternative to conventional mining. The Company has a near-term extraction profile of 4 million pounds of U3O8 per year from its south Texas and Wyoming ISR projects.
Long-term fundamentals underlying the uranium market continue to strengthen. Projections from industry analysts reveal annual deficits between production and utility requirements of about 40 million pounds well into 2026, with the gap approaching almost 70 million pounds per year by 2030.
With its fully licensed, low-cost U.S. ISR projects, UEC is also very well positioned to participate in the United States strategic uranium reserve. The uranium reserve budget is $1.5 billion over ten years for domestic uranium and conversion, with initial funding of $75 million approved by Congress for fiscal 2021. While predicted demand for uranium plays strongly into analysts’ forecasts, optimism is further bolstered by bipartisan support for nuclear energy that includes its inclusion into the Democratic Party’s energy platform for the first time in 48 years.
Uranium Energy Corp is a U.S.-based uranium mining and exploration company. In South Texas, the Company’s hub-and-spoke operations are anchored by the fully-licensed Hobson Processing Facility, which is central to the Palangana, Burke Hollow and Goliad ISR projects. In Wyoming, UEC controls the Reno Creek project, which is the largest permitted, pre-construction ISR uranium project in the U.S. Additionally, the Company controls a pipeline of uranium projects in Arizona, New Mexico and Paraguay, a uranium/vanadium project in Colorado and a large, high-grade ferro-titanium project in Paraguay. The Company’s operations are managed by professionals with a recognized profile for excellence in their industry, a profile based on many decades of hands-on experience in the key facets of uranium exploration, development and mining.
For more information on Uranium Energy Corp., visit the company’s website at www.UraniumEnergy.com.
NOTE TO INVESTORS: The latest news and updates relating to UEC are available in the company’s newsroom at https://ibn.fm/UEC
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
After announcing its engagement with Texas-based CPG sales agency CROSSMARK on February 2, 2021, CROSSMARK began its early-stage initiatives to bring TAAT™ to new points of sale in Ohio last week, with an objective of complementing the product’s existing presence in the state. So far, more than three quarters of Ohio retail accounts approached by CROSSMARK have stated their interest in carrying TAAT™. In Q2 2021, CROSSMARK will be servicing more than 7,000 convenience stores in Ohio. To provide greater clarity with respect to CROSSMARK’s role in the launch of TAAT™, the Company’s Chief Executive Officer Setti Coscarella appeared in a video in which Mr. Coscarella uses layperson’s terms to explain CROSSMARK’s scope of duties and how they can create value for the Company.
LAS VEGAS and VANCOUVER, British Columbia, March 05, 2021 — TAAT ™ LIFESTYLE & WELLNESS LTD. (CSE: TAAT) (OTCQB: TOBAF) (FRANKFURT: 2TP2) (the “Company” or “TAAT ™ ”) is pleased to announce that last week, national consumer packaged goods (“CPG”) sales agency CROSSMARK, Inc. (“CROSSMARK”) began its early-stage initiatives to bring TAAT™ to new points of sale, starting in Ohio to build upon the Company’s existing retail presence in that market. In a press release dated February 2, 2021 , the Company announced its engagement with CROSSMARK, an omnichannel agency for products in the CPG category based in Texas with more than 25,000 employees. CROSSMARK, which directly services over 100,000 convenience stores across the United States, has proven successful in bringing a wide range of CPG products to mainstream retail channels including an e-cigarette product that achieved dominant market share in that subset of the tobacco category. This commencement of CROSSMARK’s initiatives coincides with the February 17, 2021 launch of the TAAT™ e-commerce portal, which made TAAT™ Original , Smooth , and Menthol available to the majority of current smokers aged 21+ in the United States.
Last week, CROSSMARK began introducing all three varieties of TAAT™ to its accounts in Ohio including wholesalers and distributors of CPG and tobacco products, key retail accounts, and individual stores with whom CROSSMARK representatives have established business relationships. In Q2 2021, CROSSMARK will service over 7,000 convenience stores in the state of Ohio. The key account manager for TAAT™ in Ohio, who has more than a decade of experience in sales for a major global tobacco firm, has been leading sales training with CROSSMARK representatives to ensure that TAAT™ is positioned optimally among incumbent tobacco category offerings with an objective of capturing the attention and interest of current smokers aged 21+ and potentially persuading them to choose TAAT™ at the point of sale instead of their typical tobacco cigarette product. Through a combination of rollouts led by CROSSMARK, continued in-house efforts conducted by TAAT™ personnel, and digital advertising campaigns designed to direct smokers aged 21+ to the TAAT™ online store, the Company anticipates that these initiatives could collectively contribute to achieving greater market penetration for TAAT™ in the USD $814 billion global tobacco industry.
In addition to introducing products such as TAAT™ to potential new accounts and providing strategies to efficiently sell the product at retail, the Company has also engaged CROSSMARK to oversee the Order to Cash (“O2C”) process on its behalf. At a high level, O2C typically involves processing purchase orders and conveying the orders to wholesalers or distribution centres for fulfillment. Although such functions could be carried out internally by the Company, large-scale CPG firms often outsource O2C to third-party firms such as CROSSMARK to obviate the need to perform these functions themselves, which can become complex with products sold in multiple jurisdictions through several different wholesalers with numerous shipping points.
TAAT™ Chief Executive Officer Setti Coscarella commented, “These are exciting times for the Company as we enter the final month of Q1 2021. Now that our product line has had the opportunity to be tested by smokers aged 21+ across Ohio with consistently positive reception, we can start to roll TAAT™ out more aggressively with the knowledge that we have a solid product formulation and commercialization playbook. Last week, CROSSMARK got to work with introducing TAAT™ to its impressive portfolio of accounts in Ohio, and more than three quarters of retailers have stated an interest in carrying TAAT™ in their stores. CROSSMARK’s efforts will run concurrently with our continued in-house sales efforts and promotions for the TAAT™ online store. We are excited to see the impact CROSSMARK will have on the overall performance of TAAT™ as we continue our push to capture additional market share in the USD $814 billion global tobacco industry.”
To provide clarity with regard to the role of a sales agency such as CROSSMARK as a service provider to a CPG firm such as TAAT™, the Company has produced a video in which its Chief Executive Officer Setti Coscarella describes the dynamics between the two firms. This video is shown below, and can also be accessed by clicking here .
To view Picture 1 accompanying this release please visit:
https://www.globenewswire.com/NewsRoom/AttachmentNg/c893a25e-b37e-4035-99e7-abc6f2cbf58b
In the video shown above, TAAT™ Chief Executive Officer Setti Coscarella describes the relationship between a sales agency such as CROSSMARK and a CPG firm such as TAAT™. Last week, CROSSMARK began rolling out TAAT™ to new accounts in Ohio including wholesalers, distributors, key retail accounts, and individual stores. The video can be watched by clicking above or clicking here .
Readers using news aggregation services may be unable to view the media above. Please access SEDAR or the Investor Relations section of the Company’s website for a version of this press release containing all published media.
TAAT™ Lifestyle & Wellness Ltd. also announces that it has engaged Bay Street Communications to provide investor relations services for the Company. In connection with the engagement, the Company has entered into an Investor Relations Services Agreement with Bay Street Communications, pursuant to which it will primarily be tasked with providing the following services:
Development of a strategic investor relations plan, creation of digital media (including a new investor relations website, updated presentations, and social media content), outreach to analysts/financial media/investors, managing inbound inquiries from investors.
The services agreement has a six-month minimum term with a per-month payment value of CAD $7,000.
On behalf of the Board of Directors of the Company,
TAAT ™ LIFESTYLE & WELLNESS LTD.
“Setti Coscarella”
Setti Coscarella, CEO and Director
For further information, please contact:
TAAT™ Investor Relations
1-833-TAAT-USA (1-833-822-8872)
investor@taatusa.com
THE CANADIAN SECURITIES EXCHANGE (“CSE”) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS RELEASE, NOR HAS OR DOES THE CSE’S REGULATION SERVICES PROVIDER.
About TAAT ™ Lifestyle & Wellness Ltd.
The Company has developed TAAT™, which is a tobacco-free and nicotine-free alternative to traditional cigarettes offered in “Original”, “Smooth”, and “Menthol” varieties. TAAT™’s base material is Beyond Tobacco™, a proprietary blend which undergoes a patent-pending refinement technique causing its scent and taste to resemble tobacco. Under executive leadership with “Big Tobacco” pedigree, TAAT™ was launched first in the United States in Q4 2020 as the Company seeks to position itself in the $814 billion 1 global tobacco industry.
For more information, please visit http://taatglobal.com .
- POAI completes two separate fundraising initiatives: private placement, direct offering.
- Two fundraising campaigns expected to result in $17.6 million, $7.4 million respectively.
- Predictive Oncology plans to use funds to pay off debt as well as for working capital, general corporate purposes.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced two funding initiatives that together total an estimated $25 million. The company has entered into securities purchase agreements with institutional and accredited investors (https://ibn.fm/WH4nw) to raise approximately $17.6 million and is involved in a direct offering that is expected to raise $7.4 million (https://ibn.fm/uSv23).
The securities purchase agreement was comprised of a total of 9,043,766 shares of common stock and warrants, offered at a purchase price of $1.95 per share. The private placement was expected to close around Feb. 22, 2021. In the announcement of the private placement, Predictive Oncology noted that it planned to use some $5.88 million of the net proceeds from the placement to pay off debt; the company has earmarked the remaining funds for general corporate purposes.
The direct offering is also between POAI and select institutional and accredited investors. Consisting of approximately 4,222,288 shares of common stock offered at a purchase price of $1.75 per share, the offering was expected to close approximately Feb. 26, 2021. The company noted that it plans to use the $7.4 million net proceeds from this placement for working capital purposes.
In the past, the pharmaceutical industry has invested heavily in genomics and big data, hoping to better understand individual patient’s genomes and deliver targeted therapeutics. In reality, the use of genomics alone has proven to be disappointing. Predictive Oncology is confident that a multi-omic approach offers much greater chance of success. Unfortunately, few comprehensive, multi-omic datasets exist, and such data is difficult to access quickly as it is both costly and time consuming to initiate prospective data collection – especially in cancer, an area where Predictive Oncology is focused.
POAI, however, is a leader in the nascent multi-omic game. The company has spent years gathering an estimated 150,000 clinically validated cases on its molecular information platform, with more than 38,000 of those specific to ovarian cancer. The data in POAI’s molecular information platform are highly differentiated, having both drug response data and access to historical outcome data from those patient samples. Predictive Oncology is focused on generating additional sequence data from these tumor samples to deliver on the unmet market need across the pharmaceutical industry for a multi-omic approach to new drug development and, most importantly, improved patient outcomes. The recently acquired funds will go far in assuring the progress of this work.
POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.
For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
With several countries across the world looking to replace the combustion engine vehicles on their roads with zero-emission electric vehicles, most automakers have had to go back to the drawing board to figure out how they will exist in a world without combustion engines. Nissan, for instance, jumped onto the electric vehicle (“EV”) bandwagon years ago with the Nissan Leaf, while automakers such as General Motors have invested heavily in EV startups while still others have started electrifying their own lineups.
In that vein, Jaguar Land Rover has announced incoming changes to its Land Rover and Jaguar brands. Within the next five years, Land Rover will unveil six new all-electric vehicle models while Jaguar, its sister brand, will be overhauled into an all-electric luxury vehicle brand by 2025. According to Jaguar Land Rover (“JLR”), all of its brands will have electric versions by 2030 as part of a company-wide review by incoming CEO Thierry Bollore.
If his plans succeed, Jaguar will be producing all-electric vehicles by then while 60% of Land Rover sales will be electric. A public statement from the company said Land Rover will produce the six electric vehicle models via its Range Rover, Defender and Discovery families, with the first pure-electric model hitting the roads in 2024. JLR’s plans for the Jaguar brand, however, aren’t as simple.
First, the automaker will have to reverse its long-term plans to develop a next-gen pure-electric XJ flagship limousine which was expected to launch this year but was put on the back burner. A statement from the company said that although it will retain the Jaguar XJ name plate, the replacement for the next-gen limousine will not be part of the lineup. However, Jaguar Land Rover has not clarified how the plan to reimagine Jaguar as an all-electric luxury vehicle brand will affect existing models such as the F-Pace, E-Pace, XE and XF.
Thierry Bollore, former CEO of Renault and incoming Jaguar Land Rover CEO, is responsible for this incoming suite of changes. Although he was appointed to replace former CEO Dr. Ralf Speth last September, he has remained under the radar as he reviews the company’s current lineup of vehicles and plans for future launches.
Jaguar Land Rover will also retain all of the production facilities it currently uses, the company’s release said, putting to rest rumors that it may have to shut down one of its UK facilities. For its pure electric models, Jaguar will employ the Electric Modular Architecture (“EMA”) while its hybrid electric and combustion engine vehicles will use the Modular Longitudinal Architecture (“MLA”) platform.
Other companies have significant EV plans for the future. Having enjoyed immense success as a global financial services provider over the years, Net Element (NASDAQ: NETE) is set to make its mark on the EV sector through a reverse merger executed with Mullen Technologies Inc., a California-based maker of electric vehicles.
NOTE TO INVESTORS: The latest news and updates relating to Net Element (NASDAQ: NETE) are available in the company’s newsroom at http://ibn.fm/NETE
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Kaival Brands Innovations Group (OTCQB: KAVL), a company focused on generating shareholder value by incubating innovative products into mature and dominant brands within their respective markets, has met a significant requirement in the process of uplisting to the Nasdaq. The company has announced that Ladenburg Thalmann & Co. Inc. has signed a market maker intention letter, indicating its commitment to make a market in Kaival shares when listed on the Nasdaq. Kaival Brans is the exclusive global distributor of all products manufactured by Bidi Vapor LLC; the Bidi(R) Stick is the fastest-growing closed system vaping product in the country and is the only vape product on the market with an ecologically friendly, mass-recycling program called Bidi(R) Cares. Combined with the other market maker commitments Kaival has obtained, Ladenburg Thalmann’s intention letter allows Kaival Brands to meet the Nasdaq market maker requirement. Ladenburg Thalmann comprises more than 4,000 financial advisors in its network and touts a rich 140-year history. “We are extremely excited and grateful to have the venerable firm, Ladenburg Thalmann, committed to making efficient and productive markets for shares of Kaival,” the company stated in the press release. “We feel as though our shareholders are all family and this is a big step towards uplisting on Nasdaq. We feel fortunate to be able to entrust our company shares to the very capable hands of these sophisticated financial traders and their tremendous retail reach.”
To view the full press release, visit https://ibn.fm/mdMKs
About Kaival Brands Innovations Group Inc.
Kaival Brands is focused on growing and incubating innovative and profitable products into mature and dominant brands in their respective markets. Kaival’s vision is to develop internally, acquire, own or exclusively distribute these innovative products and grow each into dominant market-share brands with superior quality and recognizable innovation. For more information, visit the company’s website at www.KaivalBrands.com.
NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
- CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compound
- Berubicin is CNSP’s lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (“GBM”) that was the subject of a previously conducted Phase 1 clinical trial, which had a clinical benefit response rate of 44%
- CNSP has sublicensed Berubicin to WPD Pharmaceuticals in 31 countries primarily in eastern Europe and western Asia
- WPD plans to conduct a Phase 2 trial in adults with GBM and a Phase 1 trial for pediatric patients with malignant gliomas
- CNSP intends to conduct its own Phase 2, potentially pivotal, trial in s GBM patients who have failed first-line therapy and is on track to commence the study in March 2021
- Both WPD and CNSP have received favorable opinions for their respective protocols to be used in their clinical trials
The Lower Silesian Medical Chamber Ethics Committee in Wroclaw, Poland recently gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), CNS Pharmaceuticals, Inc.’s (NASDAQ: CNSP) sublicensee in Europe and Asia for Berubicin, a positive opinion for its WPD-201 Clinical Trial Protocol to be used in the planned forthcoming Berubicin clinical trial in adults with glioblastoma multiforme (“GBM”).
Notably, a regulatory body within a given territory – in this case, Poland – shares a positive opinion to ascertain that a study, through its protocol, respects participants’ dignity, rights, safety, and well-being.
This new development, which CNSP and WPD announced in a news release recently, set the wheels in motion for the eventual approval of WPD’s studies – a multicenter Berubicin Phase 2 adult GBM trial and a multicenter pediatric Phase 1 malignant glioma trial.
“This is an important step for WPD,” commented Mariusz Olejniczak, WPD’s CEO (https://ibn.fm/PH9lC). “From both a project and sublicense agreement point of view. After receiving the Central Ethics Committee’s positive opinion, we are planning to submit our application to the Office for Registration of Medical Products, Medical Devices, and Biocidal Products, which is the Polish equivalent of the FDA. We hope to receive an approval within three months from submission.”
WPD plans to start the Phase 2 trial in the first half of 2021 and the Phase 1 trial later in 2021. This will bring the total number of Berubicin clinical trials to be started in 2021 to three as CNSP will also conduct its Phase 2 trial. CNSP’s Phase 2 trial will evaluate the efficiency and safety of Berubicin as a treatment for adults with GBM who have failed first-line therapy.
CNSP slated its study for March= 2021, having received approval from the U.S. Food and Drug Administration (“FDA”) for its Investigational New Drug (“IND”) application and a study level Central IRB approval from the Central IRB for the CNS-201 Clinical Trial Protocol.
“We are pleased for WPD to achieve this key milestone and are encouraged by their continued execution in furthering the development of Berubicin,” John Climaco, the CEO of CNS Pharmaceuticals, said. “We look forward to continuing our trial preparations, as well as WPD’s planned submissions to the Polish Competent Authority”.
Berubicin is CNSP’s novel anthracycline (a chemotherapy drug), which is notably unique from other anthracyclines. Historically, anthracyclines have never been used to treat primary or metastatic brain cancers because they did not have any demonstratable ability to cross the blood-brain barrier and achieve significant levels of activity in the brain. However, based on limited available data, it appears that Berubicin can cross the barrier (https://ibn.fm/XnOxj).
Its efficacy was demonstrated in Phase 1 clinical trial completed in 2006 by Reata Pharmaceuticals, Inc. – CNSP has since acquired all the data from this trial and is currently the exclusive Berubicin license holder, subject to the sublicense agreement with WPD. The Phase 1 trial, which has 25 participants evaluable, had an overall response rate (clinical benefit of stable disease or better) of 44%. Notably, one patient’s experience with the treatment was durable as they have remained cancer-free for well over a decade through the most recent clinical evaluation on November 6, 2020. The Phase 1 trial had a limited sample size, so there can be no guarantee that similar results will be realized in the subsequent trials, but it is promising. CNSP’s Phase 2 trial will have an estimated enrollment of over 200 participants (https://ibn.fm/C6426).
CNSP is a clinical-stage biotechnology company that focuses on developing new treatments for the brain and central nervous system’s primary and metastatic cancers. Berubicin, the Company’s lead anthracycline drug candidate, is a promising treatment for glioblastoma multiforme (GBM). WPD is a biotechnology company that focuses on researching and developing medicinal products involving biological compounds and small molecules in the oncology and virology fields. WPD holds a Berubicin sublicense for the European and Asian markets.
For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- Head CTs, MRIs are most-used but not most-effective tool for head trauma or neurological issues in triage
- EEG changed clinical management of 76.2% of patients, even when CT or MRI was available
- Brain Scientific has overcome key barriers causing EEG underuse in emergency medicine
Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company, is making EEGs accessible in emergency departments (“ED”) with cutting-edge tech that bridges the widening gap in access to quality care. As the public becomes more aware of head trauma’s long-term effects, triages fill up with potential TBIs and acute neurological conditions. Facilities are scrambling to adapt to the growing need but are often ill equipped to do so.
When a patient arrives presenting head trauma or neurological issues, almost reflexively, a head CT and/or MRI is ordered. A BRSF white paper titled “Electroencephalography in the Emergency Department” explains why this is not always the most effective diagnostic tool (https://ibn.fm/IWTxt).
The report notes that head CT is not always the optimal scan for all acute neurological conditions; however, due to its availability, it is overused. Around 70 million CT examinations are performed in EDs annually in the United States (https://ibn.fm/gwcGo). While these are ideal for brain hemorrhage, skull fractures, malignancy and a handful of other conditions, they have been found ineffective at identifying mild traumatic brain injury (“mTBI”) and nontraumatic causes of neurologic dysfunction such as syncope, delirium, and vertigo. The MRI provides higher resolution images and greater detail of the brain than the CT but is limited as a primary diagnostic tool in the ED.
According to the CDC, an estimated 2.5 million TBI-related visits are made to the ED in the U.S. a year (https://ibn.fm/cppKg). Part of the increase is due to the public’s growing knowledge of TBI effects. Neither the head CT or MRI are equipped to diagnose mTBI adequately. The best indicator is an EEG, which can determine the severity of the injury.
Delirium is also often seen in the ED and can affect up to one-half of older patients in hospitals. However, experiencing delirium in a hospital setting does not mean a patient has Alzheimer’s or another dementia diagnosis. Dementia is chronic, while delirium is usually reversible. Determining what the patient is experiencing is essential in creating a successful care plan. An EEG can make this distinction.
The American Academy of Neurology published a study on routine EEGs in emergency room and inpatient services. It was found that the use of the EEG changed the clinical management of 76.2% of patients, even when a normal CT or MRI was available (https://ibn.fm/gCNV4).
Beyond TBIs and dementia, EEGs are also used to diagnose epilepsy and other acute neurological conditions that CTs and MRIs are simply not designed to find.
So why are EEGs not used more often?
The size of traditional EEG systems, lack of portability and inadequate numbers of trained EEG personnel are key factors contributing to the underuse of the EEG in emergency medicine. Utilizing equipment that takes hours is not feasible in a triage situation. Brain Scientific has overcome these barriers with two separate devices: the NeuroCap(TM) and NeuroEEG(TM). Low cost, portable, small, wireless, and easy to set up, these devices make it possible for EEGs to be utilized in emergency departments across the country.
To learn more about this company, visit www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Brain Scientific (OTCQB: BRSF) is focused on modernizing brain diagnostics through cutting-edge technologies. The company’s NeuroCap(TM) offers a cost-effective, disposable solution that has the ability to bridge the gap in access to neurological testing. A recent article discussing this reads, “The NeuroCap has clear advantages to its bulkier EEG counterpart. The bulkier version requires a skilled specialist to administer, comes with metal disks and wires, requires constant cleaning and sterilization, and takes up to 30 minutes to administer, not including prep or cleaning time. With the NeuroCap, clinical personnel can apply the disposable headset in five minutes or less. This allows for EEGs to be administered in almost any location, including the patient’s home or nursing homes, assisted living facilities or clinics. In addition, because the cap is disposable, there is no need to sanitize after each use; the device is also compatible with conventional EEG amplifiers. The data can be reviewed and evaluated through third-party software, reducing the need for a neurologist to be on site.”
To view the full article, visit: https://ibn.fm/lxHkT
About Brain Scientific Inc.
Brain Scientific is a commercial-stage health-care company with two FDA-cleared products, providing next-gen solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company’s corporate strategy, devices or for investor relations, visit www.BrainScientific.com.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at http://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
A recent study discovered how lower temperatures improved a surfactant’s activity, showing that therapeutic hypothermia is a possible treatment option for ARDS, which impacts roughly one-tenth of intensive care unit (“ICU”) patients globally. Apart from patients in ICUs, critical coronavirus patients also suffer from acute respiratory distress syndrome.
In layman’s language, therapeutic hypothermia is the intentional cooling of an individual’s body. Research conducted by Chiara Autilio and colleagues from the Jesus Perez-Gil laboratory at the Complutense University of Madrid demonstrates how therapeutic hypothermia works at the molecular level in an individual’s lungs; the research also notes how this method could effectively be applied to acute respiratory distress syndrome.
This study was presented at the 65th Biophysical Society annual meeting, which was held virtually in February. The researchers’ findings were reported in the “Nature Scientific Reports” journal earlier in January of this year.
The study explains that the surfactant is a molecular mixture found inside the lungs, which is needed for breathing. Sometimes, premature babies are born without having developed this molecular mixture, which is why they may need emergency surfactant replacement treatments to help them breathe. It should be noted, however, that this molecular mixture is broken up in grown-ups who have lung inflammation or injuries and can also be inactivated.
The team of researchers grew curious to see how cooling would affect the surfactant after discovering therapeutic hypothermia’s use in improving breathing in premature babies and prior research, which demonstrated how it benefited acute respiratory distress syndrome (“ARDS”).
The researchers observed the isolated molecular mixture in their laboratory, with Autilio stating that they discovered an improvement in the activity of the surfactant at 33º C. They discovered that at that temperature, the molecular mixture had lower surface tension, which made it easier for oxygen to enter the lungs. The researchers also discovered that the lower surface tension altered the molecules’ activity in the surfactant, thereby hindering the mixture from being affected by blood molecules, which may happen when an individual has a lung injury.
The study’s findings suggest that therapeutic hypothermia could be used to help individuals who have acute respiratory distress syndrome to breathe. Autilio noted that clinical trials are being conducted to test whether therapeutic hypothermia could be used as a treatment for severe breathing difficulties associated with the coronavirus, adding that the team of researchers would now focus on developing a surfactant for grown-ups.
Diverse research on different health conditions is currently planned or ongoing. For instance, AzurRx BioPharma Inc. (NASDAQ: AZRX) raised more than $20 million last year to finance its planned clinical trials focusing on its drug candidate intended to treat cystic fibrosis.
NOTE TO INVESTORS: The latest news and updates relating to AzurRx BioPharma Inc. (NASDAQ: AZRX) are available in the company’s newsroom at https://ibn.fm/AZRX
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
TEMPE, Ariz., March 04, 2021 – Wrap Technologies, Inc. (Nasdaq: WRAP) (the “Company”), a global leader in innovative public safety technologies and services, today announced results for its fourth quarter and fiscal year ended December 31, 2020.
Fourth Quarter 2020 Summary
Net Sales of $1.4 million, Growth of 464%
Gross Margin of 33%
Cash, Cash Equivalents and Short-Term Investments of $41.6 million
Stock Symbol Changed to: WRAP
Full Year 2020 Summary
Net Sales of $3.9 million, Growth of 466%
Gross Margin of 34%
Sold Product to 15 New Countries – 36 Countries to Date
Trained Agencies Increased to Over 450 Agencies
BolaWrap Certified Instructors Increased to 1,360
Management Commentary – Tom Smith, President
“As public safety experienced historic challenges in 2020, WRAP adapted to a quickly-evolving market by putting increased focus on building a global brand and broadening our impact as a leader in de-escalation solutions and technology. As safe and effective uses of BolaWrap increased in the United States, the device has also been sold globally to 36 countries. Our international business is only anticipated to grow, due to a rapidly expanding pipeline and international distribution network.”
“In the wake of global protests surrounding excessive use of force, 2021 is expected to be a year focused on domestic police and public safety reform, with an increased focus from community groups, government organizations and the media on safer tactics and tools. In Q4 2020, we completed the acquisition of NSENA, Inc. with the expressed purpose of providing an immersive training solution to a market that we believe is seeking fresh ideas towards police education and training. We expect 2021 to be a year of continued growth and insights as we pursue our goal of becoming the global leader in de-escalation solutions and best practices.”
|
|
Three Months Ended |
|
Year Ended |
|
|
December 31, |
|
December 31, |
| (amounts in thousands, except per share data) |
|
2020 |
|
2019 |
|
2020 |
|
2019 |
| Total revenues |
|
$ |
1,415 |
|
|
$ |
251 |
|
|
$ |
3,944 |
|
|
$ |
697 |
|
| Net sales growth (1) |
|
|
464 |
% |
|
|
NM |
% |
|
|
466 |
% |
|
|
NM |
% |
| Gross margin rate |
|
|
33 |
% |
|
|
34 |
% |
|
|
34 |
% |
|
|
40 |
% |
| Net loss |
|
$ |
(3,556 |
) |
|
$ |
(2,543 |
) |
|
$ |
(12,580 |
) |
|
$ |
(8,325 |
) |
| Net loss per diluted share |
|
$ |
(0.10 |
) |
|
$ |
(0.09 |
) |
|
$ |
(0.37 |
) |
|
$ |
(0.29 |
) |
(1) As compared to the prior year period.
FOURTH QUARTER 2020 FINANCIAL AND OPERATIONS HIGHLIGHTS
Net Sales
- Generated revenue of $1.4 million for the 4Q20, 464% growth as compared to 4Q19.
- 40% sequential increase as compared to the 3Q20 ($1.0 million).
- The pandemic impacted 2020 sales efforts both in the U.S. and internationally. Our pipeline, however, is robust.
Gross Profit
- Generated $0.5 million of gross profit for the 4Q20.
- Gross margin was 33% for the 4Q20, a slight improvement compared to the 32% for 3Q20.
- We continue to expect our gross margins to be fluid as we ramp our revenue base during this early-stage of growth.
- Based on current initiatives, we expect to improve gross margins in future periods.
Selling, General and Administrative (SG&A) Expense
- SG&A expense increased $1.6 million in 4Q20 compared to 4Q19.
- Increase was driven primarily by a $0.8 million increase in compensation costs as we ramp our sales force and training teams, and $0.4 million of increased marketing and promotion expenditures.
Research and Development (R&D) Expense
- R&D expense increased 22% in 4Q20 to $0.7 million compared to 4Q19.
- We expect our R&D expense to increase in 2021 as we add staff and expand important research initiatives in response to identified market opportunities.
Inventory
- Inventory increased to $2.7 million at end of 4Q20, compared to $2.0 million at 3Q20 in response to growing market opportunities.
Capital Structure and Liquidity
- Cash, cash equivalents and short-term investments was $41.6 million at end of 4Q20 compared to $45.1 million at 3Q20, representing 85% of total assets.
- In December 2020 we acquired NSENA, a virtual reality-based training simulator business targeting law enforcement and corrections. Our balance sheet at the end of 4Q20 reflected $0.3 million of assumed debt related to the NSENA acquisition.
FULL YEAR 2020 FINANCIAL AND OPERATIONS HIGHLIGHTS
Net Sales
- Generated $3.9 million of revenue in 2020, a 466% increase over 2019. The reflects the continued ramp of our business and adoption of our platform at this early stage.
- In spite of severe travel restrictions and logistic challenges caused by COVID, our international business accounted for 64% of 2020 revenue compared to 28% in 2019, reflecting 1,188% growth.
- We have sold BolaWrap products to 36 countries, adding 15 new countries in 2020 in spite of travel restrictions.
- The number of international distributors grew from 16 at the end of 2019 to 35 at the end of 2020.
Gross Profit
- Generated $1.3 million of gross profit in 2020. Our gross margin for 2020 was 34%.
Selling, General and Administrative (SG&A) Expense
- SG&A expense increased $5.0 million in fiscal 2020, which reflects our investment in our business during our initial ramp in sales and production.
Research and Development (R&D) Expense
- R&D expense increased $0.6 million in 2020 due to increased staffing.
Non-Cash Stock Compensation Expense
- Operating expense included $2.2 million of non-cash stock compensation expense in 2020 compared to $1.5 million in 2019.
Outlook
We continue to expect near-term headwinds to our growth as international travel remains limited. We expect this to continue through at least the first half of 2021 then soften as we proceed through the second half of 2021.
Webcast and Earnings Conference Call
The Company will host a live Zoom video webcast for investors and other interested parties beginning at 4:30 p.m. Eastern Time on Thursday, March 4, 2021. The call will be hosted by Tom Smith, President; Jim Barnes, CFO; and Paul Manley, VP of Investor Relations.
WEBCAST LINK: Webcast Registration Link
Participants may access the live webcast by visiting the Company’s Investor Relations page at www.wrap.com . A webcast replay of the call will be available on the Company’s Investor Relations page within 24 hours of the live call ending.
Contact
Investors and Media:
Paul M. Manley
Vice President of Investor Relations
(612) 834-1804
pmanley@wrap.com
About Wrap Technologies
WRAP Technologies (Nasdaq: WRAP) is a global leader in innovating public safety technologies and services that deliver advanced solutions focused on avoiding escalation. The BolaWrap® Remote Restraint device, WRAP’s first product, is a patented, hand-held device that discharges a Kevlar® tether to temporarily restrain from a safe distance. Through many field uses and growing adoption by agencies across the globe, BolaWrap is proving to be an effective tool to safely detain persons without injury. WRAP Reality, the Company’s virtual reality training system, is an immersive training simulator and comprehensive public safety training platform designed to empower first responders with the necessary knowledge to perform in the field. WRAP’s headquarters are located in Tempe, Arizona. For more information, please visit wrap.com .
Use of Non-GAAP Information
Included in this press release are non-GAAP operational metrics regarding distributors, agencies and training and amounts of non-cash stock-based compensation expense, which the Company believes provide helpful information to investors with respect to evaluating the Company’s performance.
Trademark Information
BolaWrap, Wrap and Wrap Reality are trademarks of Wrap Technologies, Inc. All other trade names used herein are either trademarks or registered trademarks of the respective holders.
Cautionary Note on Forward-Looking Statements – Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to: statements regarding the Company’s overall business; total addressable market; and, expectations regarding future sales and expenses. Words such as “expect”, “anticipate”, “should”, “believe”, “target”, “project”, “goals”, “estimate”, “potential”, “predict”, “may”, “will”, “could”, “intend”, and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Moreover, forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the Company’s ability to successful implement training programs for the use of its products; the Company’s ability to manufacture and produce product for its customers; the Company’s ability to develop sales for its new product solution; the acceptance of existing and future products; the availability of funding to continue to finance operations; the complexity, expense and time associated with sales to law enforcement and government entities; the lengthy evaluation and sales cycle for the Company’s product solution; product defects; litigation risks from alleged product-related injuries; risks of government regulations; the business impact of health crises or outbreaks of disease, such as epidemics or pandemics; the ability to obtain export licenses for counties outside of the US; the ability to obtain patents and defend IP against competitors; the impact of competitive products and solutions; and the Company’s ability to maintain and enhance its brand, as well as other risk factors mentioned in the Company’s most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events or changes in its expectations.
| Wrap Technologies, Inc. |
| Condensed Consolidated Balance Sheets |
| (unaudited – dollars in thousands) |
|
|
|
|
|
|
|
December 31,
|
|
|
|
2020 |
|
|
|
2019 |
|
| ASSETS |
|
|
|
|
| Current assets: |
|
|
|
|
| Cash and cash equivalents |
|
$16,647 |
|
|
$16,984 |
|
| Short-term investments |
|
|
24,994 |
|
|
|
– |
|
| Accounts receivable, net |
|
|
1,871 |
|
|
|
195 |
|
| Inventories, net |
|
|
2,655 |
|
|
|
2,245 |
|
| Prepaid expenses and other current assets |
|
|
760 |
|
|
|
251 |
|
| Total current assets |
|
|
46,927 |
|
|
|
19,675 |
|
| Property and equipment, net |
|
|
357 |
|
|
|
243 |
|
| Operating lease right-of-use asset, net |
|
|
139 |
|
|
|
261 |
|
| Intangible assets, net |
|
|
1,396 |
|
|
|
230 |
|
| Other assets, net |
|
|
13 |
|
|
|
13 |
|
| Total assets |
|
$48,832 |
|
|
$20,422 |
|
|
|
|
|
|
| LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
| Current liabilities: |
|
|
|
|
| Accounts payable and accrued liabilities |
|
$1,953 |
|
|
$601 |
|
| Customer deposits |
|
|
2 |
|
|
|
344 |
|
| Deferred revenue |
|
|
16 |
|
|
|
3 |
|
| Operating lease liability – short term |
|
|
94 |
|
|
|
128 |
|
| Note payable to bank – short term |
|
|
275 |
|
|
|
– |
|
| Total current liabilities |
|
|
2,340 |
|
|
|
1,076 |
|
| Long-term liabilities |
|
|
79 |
|
|
|
150 |
|
| Total liabilities |
|
|
2,419 |
|
|
|
1,226 |
|
| Stockholders’ equity |
|
|
46,413 |
|
|
|
19,196 |
|
| Total liabilities and stockholders’ equity |
|
$48,832 |
|
|
$20,422 |
|
| Wrap Technologies, Inc. |
| Condensed Consolidated Statements of Operations and Comprehensive Loss |
| (unaudited – dollars In thousands, except share and per share data) |
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31, |
Year Ended December 31, |
|
|
|
2020 |
|
|
|
2019 |
|
|
|
2020 |
|
|
|
2019 |
|
| Revenues: |
|
|
|
|
|
|
|
|
| Product sales |
|
$1,382 |
|
|
$237 |
|
|
$3,868 |
|
|
$656 |
|
| Other revenue |
|
|
33 |
|
|
|
14 |
|
|
|
76 |
|
|
|
41 |
|
| Total revenues |
|
|
1,415 |
|
|
|
251 |
|
|
|
3,944 |
|
|
|
697 |
|
| Cost of revenues |
|
|
942 |
|
|
|
165 |
|
|
|
2,601 |
|
|
|
420 |
|
| Gross profit |
|
|
473 |
|
|
|
86 |
|
|
|
1,343 |
|
|
|
277 |
|
|
|
|
|
|
|
|
|
|
| Operating expenses (i): |
|
|
|
|
|
|
|
|
| Selling, general and administrative |
|
|
3,698 |
|
|
|
2,106 |
|
|
|
11,631 |
|
|
|
6,653 |
|
| Research and development |
|
|
751 |
|
|
|
616 |
|
|
|
2,789 |
|
|
|
2,237 |
|
| Total operating expenses |
|
|
4,449 |
|
|
|
2,722 |
|
|
|
14,420 |
|
|
|
8,890 |
|
| Loss from operations |
|
|
(3,976 |
) |
|
|
(2,636 |
) |
|
|
(13,077 |
) |
|
|
(8,613 |
) |
|
|
|
|
|
|
|
|
|
| Other income (expense): |
|
|
|
|
|
|
|
|
| Interest income |
|
|
2 |
|
|
|
95 |
|
|
|
83 |
|
|
|
291 |
|
| Other |
|
|
418 |
|
|
|
(2 |
) |
|
|
414 |
|
|
|
(3 |
) |
|
|
|
420 |
|
|
|
93 |
|
|
|
497 |
|
|
|
288 |
|
| Net loss |
|
($3,556 |
) |
|
($2,543 |
) |
|
($12,580 |
) |
|
($8,325 |
) |
|
|
|
|
|
|
|
|
|
| Net loss per basic common share |
|
($0.10 |
) |
|
($0.09 |
) |
|
($0.37 |
) |
|
($0.29 |
) |
| Weighted average common shares used to compute net loss per basic common share |
|
|
37,399,195 |
|
|
|
29,704,067 |
|
|
|
33,846,338 |
|
|
|
28,652,625 |
|
|
|
|
|
|
|
|
|
|
| Comprehensive loss: |
|
|
|
|
|
|
|
|
| Net loss |
|
($3,556 |
) |
|
($2,543 |
) |
|
($12,580 |
) |
|
($8,325 |
) |
| Net unrealized gain on short-term investments |
|
|
8 |
|
|
|
– |
|
|
|
15 |
|
|
|
– |
|
| Comprehensive loss |
|
($3,548 |
) |
|
($2,543 |
) |
|
($12,565 |
) |
|
($8,325 |
) |
|
|
|
|
|
|
|
|
|
| (i) includes stock-based compensation expense as follows: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended December 31, |
Year Ended December 31, |
|
|
|
2020 |
|
|
|
2019 |
|
|
|
2020 |
|
|
|
2019 |
|
| Selling, general and administrative |
|
$1,538 |
|
|
$1,408 |
|
|
$1,957 |
|
|
$1,410 |
|
| Research and development |
|
|
84 |
|
|
|
(70 |
) |
|
|
280 |
|
|
|
126 |
|
| Total stock-based compensation expense |
|
$1,622 |
|
|
$1,338 |
|
|
$2,237 |
|
|
$1,536 |
|
| Wrap Technologies, Inc. |
| Condensed Consolidated Statements of Cash Flows |
| (unaudited – dollars in thousands) |
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2020 |
|
|
|
2019 |
|
| Cash Flows From Operating Activities: |
|
|
|
|
| Net loss |
|
|
($12,580 |
) |
|
|
($8,325 |
) |
| Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
| Depreciation and amortization |
|
|
163 |
|
|
|
47 |
|
| Warranty provision |
|
|
30 |
|
|
|
13 |
|
| Inventory obsolescence |
|
|
(68 |
) |
|
|
(194 |
) |
| Non-cash lease expense |
|
|
122 |
|
|
|
80 |
|
| Share-based compensation |
|
|
2,237 |
|
|
|
1,536 |
|
| Debt forgiveness income |
|
|
(416 |
) |
|
|
– |
|
| Non-cash interest expense |
|
|
2 |
|
|
|
– |
|
| Common shares issued for services |
|
|
– |
|
|
|
103 |
|
| Provision for doubtful accounts |
|
|
10 |
|
|
|
– |
|
| Changes in assets and liabilities: |
|
|
|
|
| Accounts receivable |
|
|
(1,686 |
) |
|
|
(191 |
) |
| Inventories |
|
|
(343 |
) |
|
|
(1,893 |
) |
| Prepaid expenses and other current assets |
|
|
(508 |
) |
|
|
(136 |
) |
| Accounts payable |
|
|
825 |
|
|
|
174 |
|
| Operating lease liability |
|
|
(128 |
) |
|
|
(63 |
) |
| Customer deposits |
|
|
(342 |
) |
|
|
344 |
|
| Accrued liabilities and other |
|
|
493 |
|
|
|
112 |
|
| Deferred compensation |
|
|
– |
|
|
|
(96 |
) |
| Warranty settlement |
|
|
4 |
|
|
|
– |
|
| Deferred revenue |
|
|
(2 |
) |
|
|
3 |
|
| Net cash used in operating activities |
|
|
(12,187 |
) |
|
|
(8,486 |
) |
|
|
|
|
|
| Cash Flows From Investing Activities: |
|
|
|
|
| Purchase of short-term investments |
|
|
(34,979 |
) |
|
|
– |
|
| Proceeds from maturities of short-term investments |
|
|
10,000 |
|
|
|
– |
|
| Capital expenditures for property and equipment |
|
|
(249 |
) |
|
|
(257 |
) |
| Investment in patents and trademarks |
|
|
(129 |
) |
|
|
(114 |
) |
| Purchase of intangible assets |
|
|
(544 |
) |
|
|
– |
|
| Business acquisition |
|
|
(210 |
) |
|
|
– |
|
| Long-term deposits |
|
|
– |
|
|
|
(11 |
) |
| Net cash used in investing activities |
|
|
(26,111 |
) |
|
|
(382 |
) |
|
|
|
|
|
| Cash Flows From Financing Activities: |
|
|
|
|
| Sale of common stock and warrants |
|
|
12,400 |
|
|
|
12,500 |
|
| Offering costs paid on sale of common stock and warrants |
|
|
(733 |
) |
|
|
(1,149 |
) |
| Proceeds from exercise of warrants |
|
|
26,191 |
|
|
|
2,112 |
|
| Offering costs paid on exercise of warrants |
|
|
(1,016 |
) |
|
|
(28 |
) |
| Proceeds from exercise of stock options |
|
|
705 |
|
|
|
58 |
|
| Proceeds from bank note |
|
|
414 |
|
|
|
– |
|
| Net cash provided by financing activities |
|
|
37,961 |
|
|
|
13,493 |
|
|
|
|
|
|
| Net increase (decrease) in cash and cash equivalents |
|
|
(337 |
) |
|
|
4,625 |
|
| Cash and cash equivalents, beginning of period |
|
|
16,984 |
|
|
|
12,359 |
|
| Cash and cash equivalents, end of period |
|
$ |
16,647 |
|
|
$ |
16,984 |
|
|
|
|
|
|
| Supplemental Disclosure of Non-Cash Investing and Financing Activities: |
|
|
|
|
| Business acquisition liability |
|
$ |
298 |
|
|
$ |
– |
|
| Business acquisition cost in deferred revenue |
|
$ |
15 |
|
|
$ |
– |
|
| Change in unrealized gain on short-term investments |
|
$ |
15 |
|
|
$ |
– |
|
| Right-of-use assets and liabilities recorded during period |
|
$ |
– |
|
|
$ |
341 |
|
| Issuance costs relating to warrants issued to public offering selling agent |
|
$ |
– |
|
|
$ |
206 |
|
- Effective business strategy with demonstrated focus and execution
- Valued partnerships have delivered a platform to demonstrate proof of concepts and validate product technologies
- Strong and committed leadership with a very positive outlook
CALGARY, AB, March 4, 2021 – Exro Technologies Inc. (TSXV: EXRO) (OTCQB: EXROF) (the “Company” or “Exro”), a leading clean technology company which has developed a new class of power electronics for electric motors and batteries, is issuing the following statement in response to the false and defamatory report (the “report”) from Mariner Group.
The Company believes the report was intended to manipulate the stock price downward in support of short sellers. Exro is reviewing all available legal recourses to hold the author(s) responsible for this baseless attack, which has, as of this press release, caused the stock price to decrease. Shareholders are cautioned against reacting to the false statements being made, demonstrating a lack of understanding of the Company and its partners.
A detailed summary to fact-check the report has been prepared and laid out by the following categories:
- Business strategy
- Partnerships
- Leadership
- Technology
Business strategy
In response to inaccurate claims addressing the move to EV, operating spend, position to execute with automotive, and manufacturing facilities and compliances.
In 2019, when the new Chief Executive Officer Sue Ozdemir joined the Company, there was a deep dive into eliminating barriers to commercialization. Because of the value Exro Technologies could bring to electric motors, and with the rise in the electrification of mobility applications, a shift in focus began to form. The Company began to bring on management with expertise in electric motors and automotive power electronics.
In 2020, the Company executed and out delivered on all the milestones set out at the onset of the year, including bringing on partners with the goal of demonstrating versatility in operating applications . Operational validation of Exro technology through partnerships across the electric mobility industry is positioning the Company for potential revenue generation with electric vehicle (“EV”) manufacturers, although revenue has not yet generated through any of the Company’s purchase orders and licencing agreements, which remain at the validation stage.
In October 2020 , the Company opened a new 10,000 square foot facility in Calgary, AB to deliver commercial products with in-house design, testing, and assembly. This was the first step for Exro in developing low volume manufacturing facilities with qualification for standard automotive compliances. At that time, we started our quality management program with a targeted completion date of Q3 2021.
The Company remains intensely focused on innovation through research and development (“R&D”) of power electronics across multiple segments and shows this with the more than $12M USD dedicated budget toward R&D from the recent $42M financing raised. With a strong balance sheet, focused strategy, and robust pipeline, Exro is positioned for success.
Partnerships
In response to false claims and outright distortions regarding Exro partners, their legitimate value, and quotes from the companies that were attacked.
The initial intention of Exro’s partnerships was to demonstrate versatility in operating applications. Some partnerships like Motorino Electric have already achieved this goal , and other partnerships like Potencia Industrial continue development in reaching this goal. Partnerships like SEA Electric, have even announced expanded strategy beyond initial operating application validation scope.
- Motorino Electric (“Motorino”) is more than a single storefront, with dealers across Canada that distribute Motorino products. Motorino was instrumental in Exro validation of the e-bike controller. Founder and CEO of Motorino, Steve Miloshev , previously stated that Exro-enhanced electric bike performed dramatically better in field tests.
- Aurora Powertrains (“Aurora”) continues to work alongside the Exro team in validating the Coil Driver with their innovative snowmobile. This validation would open the door to the recreational mobility segment for Exro and shed light on commercialization with Aurora in a growing electric snowmobile market.
- The partnership with Clean Seed Capital Group (“Clean Seed”) is a collaboration to begin development in advancing electrification of agricultural equipment. Exro continues to work toward this alongside the Clean Seed team, who continue to push the throttle toward innovative farming. “Years of R&D have resulted in a vast portfolio of intellectual property that sets new benchmarks in seeding and planting technologies”, stated Graeme Lempriere , Chief Executive Officer of Clean Seed. “Spring 2021 Clean Seed is commercializing its Smart Seeder MAX in Canada with a strong commitment to rapid growth.”
- Templar Electric Boats (“Templar”) owner Mark Fry quickly responded to the false claims of the report with a full statement. “I fully stand behind Exro and its management team. The Company is on the right track and has huge potential for growth. Exro has been very supportive and has worked consistently with us to develop integration of their technology for marine applications. The report falsely claims we are operating out of a UPS store, when in fact, we operate out of our factory where we develop our boats and our marina location where we demo them. If we had been contacted at all prior to the false report, we could’ve simply communicated that.”
- Potencia Industrial (“Potencia”) is a longstanding business that has been in operation for more than 50 years with experience in custom applications for electric motors. Most recently, Potencia has begun to focus on electric motors in automotive applications and have in-house electric vehicles for testing that have traveled more than 1 Million miles. “When we entered into a partnership with Exro, we knew it would be a long-term commitment, and Exro has worked with us every step of the way”, said Roberto Goffried, Chief Executive Officer of Potencia. “Due to this unwarranted attack against Exro and my company, we felt it necessary to express the great relationship we have with Exro and how delighted we are about the progress we have made together. We have crossed many milestones in integration of their technology with our electric vehicle testing. Since Sue joining there has been an elevated focus to delivering on the objectives we had set for the electric vehicles. Had an investigator actually contacted us wanting to see our facility, we would’ve happily hosted and demonstrated our products, but we did not receive any such contact.” Potencia has also provided a full report in response that can be found here.
In second quarter of 2019, Potencia issued a 500K purchase order that represents the volume supply of the Coil Driver after validation is completed. As per the press release on February 3 , the Coil Driver has been shipped to Potencia for validation due to be completed in third quarter 2021. After which point, we will begin delivery against the purchase order issued from Potencia.
It is also worth mentioning that the false report is misleadingly silent on key partnerships that may be further along in the path to technology validation and revenue and like Zero Motorcycles, Heinzmann, SEA Electric, and Exro’s recently announced LAND deal . Exro’s partners range from smaller start-ups to larger established businesses. Exro is eager to engage with any partner wishing to validate its technology and potentially purchasing its product – the more partnerships we have, the more opportunities for growth we possess. The report misrepresents Exro’s business by cherry-picking a list of some of our smaller partners. We value our relationships with all our partners and hope to grow with them as we continue to add new partners to the list.
Leadership
In response to the false attack regarding the Chairman of the Board Mark Godsy, innuendos on management positions, and outlook.
The malicious attack on Exro Chairman of the Board Mark Godsy is not substantiated with facts. Mark Godsy , previously Exro CEO until 2019 when Sue Ozdemir joined, is one of Exro’s largest shareholders and has not sold a single share of Exro to date.
Mark is an upstanding businessman who still today is licensed to practice law and has always conducted himself with the highest integrity. “I can confirm that Mark Godsy was one of my co-founders and that he was a senior executive of ID Biomedical Corporation for several years,” stated Dr. Anthony Holler , previous CEO of ID Biomedical Corporation. “Mark, myself, and others were also co-founders of Angiotech Pharmaceuticals, a medical device company.”
Current Chief Executive Officer of Exro, Sue Ozdemir , recently sold about 18% of her share position. “My selling shares was in no way a reflection of my belief in the Company,” commented Sue. “It was a purely a personal decision as my family and I went through the transition in moving to Calgary . I could not be more optimistic about our company outlook.”
More recently, you will find the Exro management team is buying into more Exro shares as they continue to execute the new business strategy since Sue’s onset.
Technology
In response to the inaccurate claims addressing marketing, product technology, and intellectual property protection.
Today, Exro is focused on leading the way to intelligent electrification. In other words, focused on being the brains of the electric vehicles and energy storage solutions for the transition to electrification. Exro technology provides solutions for optimizing systems with smart power electronics, without adding more equipment.
Accomplishing coil switching electronically, without external mechanical gearboxes, is something that has not been done before. There has not been a cost-effective solution, prior to the Coil Driver , to bring this type of technology to mass market. Exro has validated the Coil Driver for operating applications up to the micro controller size today and continues to work with partners to validate the product line through the range of mobility applications.
The Coil Driver technology can impact a wide range of applications, including drones, but the Company has not taken a focused approach to this segment or has since reviewed the strategy with prior project implementations since previous management had paused that R&D.
The Company has 17 patents granted and 18 patents pending that secure the intellectual property related to both the Coil Driver and Battery Control System (formerly Battery Management System). The Battery Control System takes battery management to the next level by gaining cell-level control. It is worth noting, that many of the patents protecting the battery control technology, are still in pending phase and thus not available to the public yet.
Summary
The Company has tried to address all of the false claims made in a report that were full of inaccuracies, innuendos, and outright distortions. Exro has a focused business strategy with demonstrated execution, valued and validated partners who are deeply invested in the success of our development projects. As well as a strong leadership team from the Board of Directors to the Management team who hold integrity and continued execution to the upmost values with a strong bank account of over $40M USD to deliver on our commitments.
Exro has professional research analysts who cover comprehensive due diligence with Raymond James and Haywood Capital. The Company encourages shareholders and engaged followers to reach out to these real analysts and find out what they have to say about Exro and its business.
“After seeing all the incredible support our company has received from valued partners, employees, engaged followers, and many more in reaction to this ruthless report– I could not be more confident in our path ahead to success,” commented Sue Ozdemir , Chief Executive Officer of Exro. “Our focus will continue to remain on executing an outstanding business strategy, delivering high quality products to the market, and continuous innovation through R&D.”
For more information about this response, please visit Exro news at www.exro.com/news
About Exro Technologies Inc.
Exro is a clean technology company pioneering intelligent control solutions in power electronics to help solve the most challenging problems in electrification. Exro has developed a new class of control technology that expands the capabilities of electric motors, generators, and batteries. Exro enables the application to achieve more with less energy consumed.
Exro’s advanced motor control technology, the Coil Driver, expands the capabilities of powertrains by enabling two separate torque profiles within a given motor. A major advancement in the sector, dynamic motor configuration enables efficiency optimization for each operating mode resulting in reduction of energy consumption. The controller automatically selects the appropriate configuration in real time so that power and efficiency are intelligently optimized.
For more information visit our website at www.exro.com .
LinkedIn https://www.linkedin.com/company/exro-technologies-inc
Twitter https://twitter.com/exrotech
Facebook https://www.facebook.com/exrotech/
ON BEHALF OF THE BOARD OF DIRECTORS
Sue Ozdemir , Chief Executive Officer
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements and forward-looking information (together, “forward-looking statements”) within the meaning of applicable securities laws. All statements, other than statements of historical facts, are forward-looking statements. Generally, forward-looking statements can be identified by the use of terminology such as “plans”, “expects”, “estimates”, “intends”, “anticipates”, “believes” or variations of such words, or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will be taken”, “occur” or “be achieved”. Forward looking statements involve risks, uncertainties and other factors disclosed under the heading “Risk Factors” and elsewhere in the Company’s filings with Canadian securities regulators, that could cause actual results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Although the Company believes that the assumptions and factors used in preparing these forward-looking statements are reasonable based upon the information currently available to management as of the date hereof, actual results and developments may differ materially from those contemplated by these statements. Readers are therefore cautioned not to place undue reliance on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed times frames or at all. Except where required by applicable law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF), an investment company, and its investee company PowerTap Hydrogen Fueling Corp. have announced their support for a recent announcement made by the city of Petaluma, California. The city has banned new gas stations in a move designed to encourage the deployment of hydrogen fueling and battery electric charging stations, a move that Clean Power Capital and PowerTap applaud. The city ban is in accordance with California’s previously announced directive that all new vehicles in the state be emission free by 2035. “The recent announcements by Petaluma, California, and the State of California are consistent with our thesis that to support hydrogen vehicles (cars and long trucks) that will be hitting the road in the coming few years, significantly more hydrogen fueling stations will be needed (over the current available — 44 in California) in California and the rest of the USA,” said PowerTap CEO Raghu Kilambi in the press release. “Our PowerTap onsite hydrogen production technology is currently being used for private hydrogen stations in the USA and a public station near LAX, and we look forward to installing our new PowerTap 3 to be deployed at existing gas stations starting in the second half of 2021. Our business plan is to install 500+ stations across the USA in the next five years.”
To view the full press release, visit http://ibn.fm/QA4MF
About Clean Power Capital Corp.
Clean Power is an investment company that specializes in investing in private and public companies opportunistically that may be engaged in a variety of industries, with a current focus in the health and renewable energy industries. In particular, Clean Power’s investment mandate is focused on high-return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and seeking liquidity in its investments. For more information about the company, please visit www.CleanPower.Capital.
NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at http://ibn.fm/MOTNF
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announced that it has completed its corporate rebranding efforts. Those efforts included the launch of a completely redesigned website. XPhyto chose to rebrand itself as part of its commitment to operational achievement in 2021, which included a number of product-development programs advancing from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto is targeting focused investment in impact-driven innovation as well as value creation through commercialization of its development pipeline. “The company is excited to introduce a fresh look at such a pivotal point in our business growth,” said XPhyto director and CEO Hugh Rogers in the press release. “With all technical requirements fulfilled, we are on the cusp of two major commercial milestones related to our rapid point-of-care COVID-19 PCR test system. With expected ISO certification and CE-IVD approval pending, we are excited to enter the next phase of our business with a positive, crisp and energetic new image.”
To view the full press release, visit http://ibn.fm/bvd1D
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at http://ibn.fm/XPHYF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications that go beyond the standard of care for anxiety and depression. A recent article discussing this reads, “Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these substantial issues. For example, FDA-approved oral antidepressants are slow to act and are associated with significant potential side effects such as anxiety, nausea and vomiting, somnolence and sexual dysfunction. VistaGen’s PH10 is an innovative pherine nasal spray designed to have rapid-onset therapeutic potential in several neuropsychiatric indications involving depression. Following completion of successful exploratory Phase 2A clinical development, the company is preparing to launch a planned Phase 2B clinical study of PH10 in major depressive disorder in early 2022. With its rapid-onset pharmacology, potential lack of systemic exposure and favorable safety results observed in all clinical studies to date, PH10 has potential to go beyond the current standard of care for depression as a novel stand-alone treatment for multiple depression disorders.”
To view the full article, visit: https://ibn.fm/X5Pkn
About VistaGen Therapeutics Inc.
VistaGen is a biopharmaceutical company committed to developing and commercializing innovative medicines with potential to go beyond the current standard of care for anxiety, depression and other CNS disorders. Each of VistaGen’s three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit www.VistaGen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at http://ibn.fm/VTGN
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
The Alkaline Water Company (NASDAQ: WTER) (CSE: WTER) has announced that its Alkaline88(R) line of bottled water will soon be available in Mexico through Tiendas Sindicales, a superstore grocery chain based in Mexico; Tiendas Sindicales is also a food service and vending service provider. WTER partnered with Tiendas Sindicales to enter Mexico, which is one of the largest bottled water markets in the world; the country reported a per capita consumption of 73.7 gallons in 2019, with eight out of 10 Mexican citizens regularly consuming bottled water. The market is ideal for The Alkaline Water Company Inc., a producer of premium bottled alkaline water along with flavor-infused waters and CBD-infused products sold under the brand names Alkaline88, A88 Infused(TM) and A88CBD(TM), respectively. Tiendas Sindicales provides consumer products through grocery stores, cafeterias and vending machines in all of the Maquiladora factories in the Mexican Free Trade Zone, a potential target audience of six million people every month. “We believe this is a significant opportunity for us to ‘test the waters’ in a major international market and that this expansion marks the beginning of our international brand presence,” said The Alkaline Water Company Inc. president and CEO Richard Wright in the press release. “This is our first step into Mexico and expect this will lead to additional opportunities in North America and other foreign jurisdictions. We continue to dominate the U.S. supermarkets and expect similar results in the Mexican and other international markets. As with all our current customers, we expect to exceed Tiendas’ forecast as our friends in Mexico enjoy the smooth clean taste of Alkaline88.”
To view the full press release, visit http://cnw.fm/4YYT5
About The Alkaline Water Company
Founded in 2012, The Alkaline Water Company is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88(R), is a leading premier alkaline water brand available in bulk and single-serve sizes along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88(R) delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts its trademarked label Clean Beverage. Quickly being recognized as a growing lifestyle brand, Alkaline88(R) launched A88 Infused(TM) in 2019 to meet consumer demand for flavor-infused products. A88 Infused(TM) flavored water is available in seven unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched A88 Infused Beverage Division Inc., which includes the company’s CBD water and flavor-infused water. For the company’s topical and ingestible offerings, A88 Infused Products includes both the company’s lab-tested, full-spectrum hemp salves, balms, lotions, essential oils and bath salts, along with broad-spectrum hemp beverage shots, powder packs, oil tinctures, capsules and gummies. To learn more about the company, please visit www.A88CBD.com and www.TheAlkalineWaterCo.com.
NOTE TO INVESTORS: The latest news and updates relating to WTER are available in the company’s newsroom at http://cnw.fm/WTER
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
- Microcap stocks outperforming 2020 record highs, currently trading at 40% above 200-day moving average
- SRAX’s Sequire SaaS platform provides public companies with tools to monitor trading activity, provides actionable insights for use in marketing campaigns
- Sequire subscriber base surged to 3 million active traders across 90 public companies since its 2019 inception
Investor interest sent microcap stocks sky-high in 2020, a trend that is continuing well into 2021 with returns on some microcap ETFs surging at several times the rate of comparable large-cap ETFs (https://ibn.fm/Bu86D). As the tide of investor interest continues to flow into microcaps, public companies are leveraging the power of data through Sequire, SRAX’s (NASDAQ: SRAX) investor analytics SaaS platform that unlocks data and insights critical to targeted marketing campaigns in order to engage current traders and attract new investors.
Small caps – companies generally valued between $50 and $300 million – are typically thought to be more volatile and riskier when compared to established companies. Throughout 2020 and so far in 2021, that risk has paid off for investors willing to take a chance on new companies – particularly those included by SRAX subsidiary LD Micro in its North American microcap index which comprises nearly 1200 companies over 14 sectors (https://ibn.fm/m58cx).
“I cannot believe what I’ve seen in the past year,” said LD Micro President Chris Lahiji. “The LD Micro Index has more than tripled from its March 2020 lows. The tiniest public companies were also some of the biggest winners last year, and already year-to-date.”
After surging 20% in 2020, the Russell 2000 continues to outperform its historic highs and is now trading at 40% above its 200-day moving average as retail traders flood the market amid low interest rates and increased fiscal stimulus. The resulting investor interest has left many public companies looking for insights into trading activity to facilitate communications and gauge investor sentiment.
Sequire provides clarity for public companies via access to tools which help them monitor shareholder buying and selling activity while tracking key investors and outstanding warrants. The service also features applications that allow subscribers to publish company-specific news and obtain stakeholder opinions through customized surveys. The platform has experienced staggering growth since its 2019 inception to include over 3 million active retail investors across 90+ public companies (https://ibn.fm/sPoOj).
“We have been discussing the importance of retail investors in public companies since the inception of Sequire,” said SRAX CEO and Founder Christopher Miglino. “It’s the very reason why we built the platform and related tools – to help companies effectively communicate with these investors.”
As the importance of data increases across the digital landscape, SRAX maintains its commitment to build the largest and most reliable opted-in data sets across a broad range of industry verticals. Through its specialized suite of applications and tools, the Company focuses on providing brands and companies across the CPG, luxury, lifestyle and financial spaces with high-quality data that provides critical, actionable insights integral to strategic marketing campaigns.
For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
Pressure BioSciences (OTCQB: PBIO) (“PBI”) founder, president and CEO Ric Schumacher was a guest on a recent episode of “Emerging Technology Insider,” which regularly releases video conversations with management of technology companies with business or financial objectives. During the interview, Schumacher focused on the company’s recently announced food industry consortium partnership with The Ohio State University and the impact it may have on the food industry. The agreement between PBI and the College of Food, Agricultural, and Environmental Sciences at Ohio State calls for PBI to install several models of its patented Ultra Shear Technology(TM) (“UST”) platform in the state-of-the-art Ohio State food pilot plant. The plant provides careful temperature and pressure control. During the interview, Schumacher noted that members of the consortium will have first access to the UST test systems and food applications developed in the pilot plant, including licensing opportunities to leverage new applications of PBI’s UST platform and other consortium-developed IP. Schumacher also noted several primary goals and benefits for food companies that join the consortium, which will be comprised of many global, well-known, leading food and beverage companies from around the world. For instance, UST, which is PBI’s proprietary method for homogenizing immiscible liquids, could potentially result in the availability of food that offers greater safety, improved absorption, better taste/smell/texture, longer room temperature shelf life and more “clean labels” (reduced or no unwanted chemical additives). The consortium will focus on advancing the commercialization of PBI’s UST platform through the quality enhancement of beverages and liquid foods, including many dairy products, condiments and sauces. The group will also focus on identifying methods to reduce costs of processing, shipping, distribution, storage and spoilage through extended room temperature stability, without compromising quality or sensory experience of the products.
To view the full press release, visit http://ibn.fm/cMHra
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. PBIO’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented-enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). The company’s primary focus is on the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of PBIO’s pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room-temperature, stable, low-acid liquid foods that cannot be effectively preserved using existing nonthermal technologies. For more information, visit the company website at www.PressureBioSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division. A recent article discussing this reads, “Predictive Oncology is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.”
To view the full article, visit: https://ibn.fm/qGVfn
About Predictive Oncology Inc.
Predictive Oncology operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. For more information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Ideanomics (NASDAQ: IDEX), on March 3, 2021, entered into an investment agreement with Energica Motor Company S.p.A pursuant to which Ideanomics invested Euro 10,909,091 for 6,128,703 ordinary shares of Energica at a subscription price of Euro 1.78 for each ordinary share. Upon purchase of the shares, Ideanomics will hold at least 20% of Energica’s share capital. Energica is the world’s leading manufacturer of high-performance electric motorcycles and the sole manufacturer of the FIM Enel MotoE(TM) World Cup. “We are proud to be part of this unified platform of which we fully share the vision,” said Livia Cevolini, CEO of Energica, of the investment. “The creation of a network of innovative companies can only accelerate the growth and adoption of new technologies such as sustainable mobility that sees us among the leaders. We are confident to make our contribution derived from decades of experience in the field of high-performing electric motorcycles. The investment will give further strength to the Energica growth already underway in recent years thanks to the innovations brought to our products within the racing experience in MotoE.”
For more details, visit http://ibn.fm/Q1qtS
About Ideanomics
Ideanomics is a global company that facilitates the adoption of commercial electric vehicles and supports next-generation financial services and fintech products. Its electric vehicle division, Mobile Energy Global (“MEG”) provides group purchasing discounts on commercial electric vehicles, EV batteries and electricity, as well as financing and charging solutions; the company refers to this business model as sales to financing to charging (“S2F2C”). Ideanomics Capital provides fintech services that include intelligent and innovative solutions powered by AI and blockchain. Together, MEG and Ideanomics Capital provide global customers and partners with more efficient solutions for a greener economy. The company is headquartered in New York City, New York, with offices in Beijing, Hangzhou and Qingdao and operations in the U.S., China, Ukraine, and Malaysia. For more information, visit www.Ideanomics.com.
NOTE TO INVESTORS: The latest news and updates relating to IDEX are available in the company’s newsroom at http://ibn.fm/IDEX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Excellon Resources (TSX: EXN) (NYSE American: EXN) (FSE: E4X2) is a producer of silver and base metals with precious metal exploration and development projects in Mexico, Idaho and Germany. Since its 1987 founding, the company has been advancing a precious metals growth pipeline focused on creating wealth for its stakeholders by realizing strategic opportunities in the silver and gold markets. A recent article discussing the company reads, “Excellon is an active and influential member of the Mining Association of Canada (‘MAC’). The company implements a practical, best-in-class management system that addresses the safety, health, security, environmental and community aspects of its operations, per the UN Sustainable Development Goals. On each project, Excellon Resources incorporates MAC’s Towards Sustainable Mining Initiatives and other world-class best practices with the objective of constantly improving its safety systems, training and hazard recognition.”
To view the full article, visit https://ibn.fm/dgkNJ
About Excellon Resources Inc.
Excellon’s vision is to create wealth by realizing strategic opportunities through discipline and innovation for the benefit of its employees, communities and shareholders. The company is advancing a precious metals growth pipeline that includes: Platosa, Mexico’s highest-grade silver mine since production commenced in 2005; Kilgore, a high-quality gold development project in Idaho with strong economics and significant growth and discovery potential; and an option on Silver City, a high-grade epithermal silver district in Saxony, Germany with 750 years of mining history and no modern exploration. The company also aims to continue capitalizing on current market conditions by acquiring undervalued projects. Additional details on Excellon’s properties are available at www.ExcellonResources.com.
NOTE TO INVESTORS: The latest news and updates relating to EXN are available in the company’s newsroom at http://ibn.fm/EXN
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
During the last quarter of 2020, the mining and metals industry in North America registered a 6.98% decline in cross-border deal activity. This is according to the most recent data from analysis conducted by GlobalData, which compared numbers from 2020’s last quarter to the average of the last four quarters.
While the average of the last four quarters had 43 cross-border deals, 2020’s final quarter announced 40 cross-border deals in the region, which were valued at $2.4 billion.
With regard to all types of deals, M&A witnessed the most activity in last year’s final quarter with 38 deals, which made up a 95% share for the region. This was led by the Teranga Gold acquisition by Endeavour Mining, which was valued at $1.86 billion.
Endeavour Mining is the top gold producer in West Africa. The acquisition of Teranga Gold added another operating asset to the company’s four mines in Burkina Faso. Additionally, this acquisition provided exposure to the Massawa project in Senegal, which Teranga Gold had acquired from Barrick Gold in 2019.
The company also acquired Semafo, which would boost the company’s growth. With six operating mines in Côte d’Ivoire as well asBurkina Faso and Senegal under its belt, Endeavour Mining will be producing roughly 1.5 million ounces of gold annually.
The other deals were a venture financing deal and a private equity deal, with each deal making up 2.5% of the remaining 5% share of the cross-border deal activity for last year’s final quarter.
With regard to the value of these cross-border deals, the M&A was the first category in the metal and mining industry of Canada. It was valued at a whopping $2.39 billion while the venture financing deals totaled $1.96 million.
During last year’s final quarter, the top-five, cross-border deals in the mining and metals industry made up 97.6% of the overall value, with a total value of $2.34 billion.
GlobalData found the top-five cross-border deals of 2020’s final quarter to be the following:
- Teranga Gold’s $1.86 billion acquisition by Endeavour Mining
- Orion Mine Finance acquiring Greenstone Gold Mines GP at $225 million
- The acquisition of Imerys Talc Vermont, Imerys Talc Canada and Imerys Talc America by Magris Resources’ for $223 million
- Vangold Mining’s asset transaction deal with Endeavour Silver worth $18 million
- The $15 million asset transaction of Champion Iron with Deloitte Restructuring.
Away from cross-border mining deals, the gap between the supply and demand for nuclear energy is expected to reach a whopping one billion pounds by 2040, and Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) is working to produce higher amounts of uranium to meet that demand. The company currently occupies the enviable position of being the most prolific producer of uranium within the United States.
NOTE TO INVESTORS: The latest news and updates relating to Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) are available in the company’s newsroom at http://ibn.fm/UUUU
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
The development of a new class of pharmaceutical medications made from psychedelic fungi and plants has brought medical science closer to making breakthroughs that address the global mental health crisis caused by the pandemic. These drugs have shown massive potential in the treatment of chronic depression.
However, there are challenges that come with the development of standardized organic compounds to help treat more than a billion individuals globally for various mental health conditions.
Frankly speaking, it’s complicated and costly to separate active ingredients in multi-compound organic substances. Globally, this has not been done on a broad scale anywhere, primarily for two main reasons.
The first entails the logistical and technological challenges of producing these mushrooms and plants to be replicated in large numbers for their chemical consistency and potency while the second factor stems from the fact that, until recently, psychedelics had been banned from being researched from the 1970s. The ban was imposed because the substances were considered drugs that did not offer any medical efficacy and would likely be misused.
Despite many years of psychedelics prohibition, societal barriers that would hinder the acceptance of psychedelics as reputable forms of medicine seem to be fading away. This would explain why laws that govern drugs have slackened to permit clinical studies on these substances, with the U.S. Food and Drug Administration (“FDA”) being supportive of research.
It is estimated that currently about 200 biotechnology start-up companies in Europe and North America are looking to get into the multibillion-dollar market for psychedelic therapies and legal psychedelic medications. Most of these companies are experimenting with psilocybin, the active psychedelic ingredient found in magic mushrooms that can be used to treat severe treatment-resistant depression as well as other mental health conditions.
According to the World Economic Forum, the indirect and direct costs of the mental health epidemic in the society total trillions of dollars annually. The Lancet Commission estimates that this figure will increase to $16 trillion in the near future when spending on law and order, education and social welfare as well as loss of productivity is factored in.
This is why the development of high efficacious, nonaddictive and safe psychedelic drugs could not come at a better time. Studies have shown that roughly 2 billion individuals are affected by addictions, disorders and other mental conditions that can be treated using psychedelic compounds. These include individuals who experience PTSD, addictions to cigarettes and alcohol, depression and anxiety.
With enough clinical evidence backing the science behind psychedelics’ healing properties, demand for these psychedelic drugs is bound to surge, signaling that this is an ideal time to manufacture pharmaceutical-grade psychedelic compounds on an industrial scale.
In related news, Cybin Inc. (NEO: CYBN) (OTC: CLXPF) has announced that it has concluded a deal to access the Kernel Flow system, which will be crucial as the therapeutic potential of psychedelic medicines under research is analyzed in real time.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTC: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
- Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin
- Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space
- Acquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline
Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has announced that its recently acquired subsidiary, Adelia Therapeutics Inc., has achieved the earn-out milestones outlined for the time period in the contribution agreement between the two companies (https://ibn.fm/c6o2E). That milestone includes the successful synthesis of multiple tryptamine derivatives.
Furthermore, the synthesis of tryptamine derivatives resulted in quantities adequate enough that Adelia could initiate in vitro “Proof of Principle”; establish that an ADME/PK has been completed; and demonstrate “In Vitro” ADME “Proof of Principle” that specific synthesis modifies the metabolism of a psychedelic tryptamine.
Adelia focuses on developing medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs, which makes the company an idea fit for Cybin, as it leads the way in researching psychedelic treatment options in the mental health space. Adelia’s proprietary development strategy is based on chemical modifications to already known tryptamine derivatives that significantly alter the pharmacokinetic properties of those derivatives without changing their therapeutic potential. The company’s recent milestone is a direct result of this focus and its dedication to seeking to minimize inter-patient variability by better controlling drug metabolism without loss of efficacy.
Cybin’s acquisition of Adelia resulted in Cybin obtaining an extensive intellectual property portfolio and product pipeline that could lead to diversification beyond major depressive disorder (“MDD”) treatments and regimens. Adelia’s three-pillar development strategy includes novel therapeutics, delivery methods and therapeutic regimens focused on improving patient outcomes. The acquisition also results in Cybin gaining psychedelic derivative drug-development candidates, with the first lead compounds expected to enter clinical studies in 2021.
“We are thrilled to join forces with Adelia,” said Cybin CEO Doug Drysdale when announcing the acquisition (https://ibn.fm/T5eIg). “We see this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects. Adelia’s expertise across multiple molecules and multiple indications, could potentially give Cybin the ability to address gaps across a larger domain.”
The Adelia acquisition also combines two talented teams that share strong patient-first values and track records of innovation in the field of psychedelics. Adelia’s leadership team of accomplished scientists brings invaluable preclinical development experience that complements Cybin’s clinical experience and resources.
Cybin is a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the company’s CEO, John Climaco, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. According to the update, CNSP management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the event. Interested parties should visit https://ibn.fm/XlGLZ for more information and to register for the conference.
To view the full press release, visit http://ibn.fm/D4QcN
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. During 2021, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation. For more information, visit the company’s website at www.CNSPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at http://ibn.fm/CNSP
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
- BRSF working to improve diagnostics by leveraging AI and machine learning
- Cloud-based infrastructure, AI-assisted diagnostic analysis is in development phase
- Brain Scientific creating long-term monitoring capabilities that leads to collection of essential biomarkers
Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly.
But BRSF isn’t stopping there.
The company’s goal is to further improve diagnostics by leveraging artificial intelligence (“AI”) and machine learning processes to analyze a database of brain readings to improve diagnosis and treatment of neurological conditions.
The company is using in-house development in order to provide diagnostic interpretation assistance for health-care providers. Currently, a secure cloud-based infrastructure and AI-assisted diagnostic analysis are in the development phase.
BRSF’s remote diagnostic devices that are already in active use will be used to acquire large datasets of neurological information that will be uploaded to the company’s secure cloud technology. These neural networks of data will be used to identify patterns and biomarkers for neurological disease in the near future. Eventually, this data will be integrated with external graph datasets that contain neurological clinical and research data. When that happens, the neural networks will comb the data to detect patterns. Over time the AI will be able to make predictions that will aid neurologists and increase access to complex neuro-diagnostic expertise (https://ibn.fm/3V7Wx).
As more clinical trials and studies are done on neurological conditions, additional data is acquired. On the Neuroscience Information Framework (“NIF”), there are currently over 4,000 databases of neurological information (https://ibn.fm/7pKza). No single neurologist can attempt to evaluate that much data to discover the best treatment for the one patient under their care.
But a computer can. By creating a secure cloud of BRSF’s data that can be integrated with external datasets and using AI with machine learning to filter through the data, neurologists will be able to locate the information needed to best help their patients. The implications of this technology is huge.
An article in Forbes states that “Biomarkers of Longevity integrated with AI and machine learning techniques have the potential to help prevent age-related diseases and extend health span,” reported a “Forbes” artice (https://ibn.fm/s5MWM). “Advances in the development of biomarkers will allow doctors to assess health, quantify the effect of interventions, and produce personalized medical reports.”
Big data plus AI will make neurological care accessible in a way it has not yet been, and BRSF committed to help pave the way.
To learn more about this company, visit www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Willow Biosciences (TSX: WLLW) (OTCQX: CANSF), a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates, has released an update on the acceleration of common share warrants that was previously announced. Willow completed the acceleration, which was comprised of 9,320,478 common share purchase warrants issued on Oct. 29, 2020. The completion included the issuance of an estimated 9,259,404 additional common shares, along with cash proceeds for the company of almost $7.9 million. The company now reports a total cash balance of approximately $48.4 million. “We are grateful for the considerable support we have received from our shareholders following our recent warrant accelerations,” said Willow president and CEO Trevor Peters in the press release. “As we enter 2021, we will use the proceeds from the Acceleration alongside the $28.75 million we raised from our recent bought-deal financing to accelerate capital spending towards execution of our commercialization plan for our existing portfolio cannabinoids, and continue to explore opportunities for cannabinoids in development.”
To view the full press release, visit http://ibn.fm/MjKEB
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Vancouver, British Columbia, which produces high-purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is on the production of cannabinoids for the treatment for pain, anxiety, obesity and brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high-purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life-changing drugs. For more information about the company, visit www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@NetworkNewsWire.com
InvestorWire is part of the InvestorBrandNetwork.
Exro Technologies (TSX.V: EXRO) (OTCQB: EXROF), a leading clean-technology company that has developed a new class of power electronics for electric motors and batteries, has made available what it is calling an integrity statement from company CEO Sue Ozdemir. The statement was released in response to a report, which impacted EXRO stock, that was not affiliated in any way with Exro or the company’s management team. In her statement, Ozdemir noted that the report was full of inaccuracies, innuendos and outright distortions in what she called a “short seller attack” on the company. “We will not take this report lightly and will be preparing a detailed response in the next 48 hours against these claims to highlight this cynical attempt to hurt a real and thriving company, its shareholders and the integrity of the market,” said Exro CEO Sue Ozdemir in the letter. “I want to personally reassure our valued partners and shareholders that we continue to maintain the highest degree of integrity at Exro and embed it within our company culture. We remain very confident about our patented technology, our business plan and organizational design, and the value of the products we can bring to market.
My commitment and belief in Exro are unshaken. I stand by the company, and my entire career is a representation of my focus to building real business value and executing on deliverables to the market. We are well positioned, with working capital to execute on our milestones and become a leader in power electronics technology.”
To view the full letter, visit https://ibn.fm/QwRD5
About Exro Technologies Inc.
Exro is a clean-technology company pioneering intelligent control solutions in power electronics to help solve the most challenging problems in electrification. Exro has developed a new class of control technology that expands the capabilities of electric motors, generators and batteries. Exro enables the application to achieve more with less energy consumed. Exro’s advanced motor control technology, the Coil Driver, expands the capabilities of powertrains by enabling two separate torque profiles within a given motor. A major advancement in the sector, dynamic motor configuration enables efficiency optimization for each operating mode resulting in reduction of energy consumption. The controller automatically selects the appropriate configuration in real time so that power and efficiency are intelligently optimized. For more information about the company, please visit www.Exro.com.
NOTE TO INVESTORS: The latest news and updates relating to EXROF are available in the company’s newsroom at http://ibn.fm/EXROF
About MiningNewsWire
MiningNewsWire (MNW) is a specialized communications platform focused on developments and opportunities in the global resources sector. The company provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, MNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MNW brings its clients unparalleled visibility, recognition and brand awareness. MNW is where news, content and information converge.
To receive SMS text alerts from MiningNewsWire, text “BigHole” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.MiningNewsWire.com
Please see full terms of use and disclaimers on the MiningNewsWire website applicable to all content provided by MNW, wherever published or re-published: https://www.MiningNewsWire.com/Disclaimer
MiningNewsWire
Los Angeles, California
www.MiningNewsWire.com
310.299.1717 Office
Editor@MiningNewsWire.com
MiningNewsWire is part of the InvestorBrandNetwork.
- Holding company Clean Power Capital Corp.’s investee PowerTap, a hydrogen fueling innovator, has teamed with carbon energy credits expert Carbonomics to develop and maximize the company’s ability to use clean energy credits
- PowerTap is driven to establish a “hydrogen highway” for environmentally conscious motorists looking for an effective alternative fuel
- Clean Power Capital is a majority investor in PowerTap — a key part of Clean Power’s focus on building up health and renewable energy enterprises
- PowerTap’s next-generation hydrogen stations are also capable of generating electricity to help them continue to pump fuel during a power outage or even potentially power the entire gas stop operation where the fuel stations are located
Holding company Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) advanced its mission of helping health and renewable energy enterprises achieve their growth potential when it became a majority investor in California’s PowerTap Hydrogen Fueling Corp last fall.
PowerTap has proven to be a formidable innovator in the clean power industry through its recent agreements with the Andretti Group for fuel station location, marketing and leadership (https://ibn.fm/lF640). Now PowerTap is maximizing its ability to navigate the regulatory hurdles for obtaining certification and emission reduction credits in the United States and international markets by teaming up with Carbonomics, and expert in the process of monetizing carbon credits.
“Carbon credits are a key part of every clean energy company’s strategy, and we are pleased to partner with Carbonomics to leverage their expertise and experience to maximize carbon credit revenues,” stated PowerTap CEO Raghu Kilambi (https://ibn.fm/UUvfG). “Leading clean energy companies like Tesla have used emission-reduction credit revenues (https://ibn.fm/K8cBV) to accelerate their growth and cash flow.”
PowerTap is preparing to install its 1,250-kilogram hydrogen production and dispensing stations at some of the Andretti Group’s more than 100 retail chain stores, which are focused on fuel, convenience and food operations through facilities under the Chevron, Texaco, Shell, 76, Circle K, Pacific Pride and CFN and other brands.
The stations are noteworthy not only for their role in helping to build up a “hydrogen highway” throughout California and eventually into other parts of the country, but also because they are capable of generating electricity.
“While much less electricity is needed to produce blue hydrogen vs green hydrogen (https://ibn.fm/39Un2), PowerTap recognized that electricity shortages may affect the operation of its fueling stations,” the company stated in a recent news release acknowledging the power outages in Texas brought on by unusual freezing weather (https://ibn.fm/D9Bd3). “To address this potential issue, PowerTap’s 3rd Generation Onsite Hydrogen fueling unit will have an industrial hydrogen fuel cell that can be used to turn excess hydrogen into electricity that can be used in various capacities including powering further hydrogen production or the rest of the gas/truck stop operations.”
PowerTap is a key part of Clean Power Capital’s investment portfolio. Clean Power’s investment mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in its investments.
For more information, visit the company’s website at www.CleanPower.Capital.
NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF
About Green Car Stocks
Green Car Stocks (GCS) is a specialized communications platform with a focus on electric vehicles (EV), as well as other emerging market opportunities in the green sector. The company provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, and (5) a full array of corporate communications solutions. As a multifaceted organization with an extensive team of contributing journalists and writers, GCS is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, GCS brings its clients unparalleled visibility, recognition and brand awareness. GCS is where news, content and information converge.
To receive SMS text alerts from Green Car Stocks, text “Green” to 21000 (U.S. Mobile Phones Only)
For more information, please visit https://www.GreenCarStocks.com
Please see full terms of use and disclaimers on the Green Car Stocks website applicable to all content provided by GCS, wherever published or re-published: https://www.GreenCarStocks.com/Disclaimer
Green Car Stocks
San Francisco, California
www.GreenCarStocks.com
415.949.5050 Office
Editor@GreenCarStocks.com
Green Car Stocks is part of the InvestorBrandNetwork.
Best Penny Stocks To Watch As Entertainment Stocks Jump In March 2021
Esports & Entertainment Penny Stocks Are Jumping Big In March
If you’re looking for the best penny stocks to buy or even top stocks to watch, it’s important to pay close attention to trends. It’s easy to put a list of “trending” names together; we see it every day. But what tends to set apart traders who find early opportunities and ones that follow the crowd is the ability to identify an underlying catalyst.
Believe it or not, with millions of new traders now involved in the stock market today, sympathy sentiment has become a huge driver for the market. If you’re new to trading, in general, when I say “sympathy,” I mean that certain stocks will move because they’ve got a similar business model, similar share structure, similar “anything,” really. The fact of the matter is that when it comes to retail traders (it may be different for investors), “market themes” have become a favorite. Let me explain
Why Do Traders Look Look For Penny Stocks Moving In “Sympathy”?
I’ll give a few recent examples. First, I’ll tell you about one of the biggest sympathy trends: vaccine stocks. Early last year and still today, we saw many companies with even the slightest relation to lung treatment or having a vaccine pipeline gaining ground. Many of these companies had very little going on at the time. Some hadn’t released positive news in months, sometimes years.
But, since they had some exposure to popular companies that actually had fundamental catalysts, traders played the sympathy trend. This is where we see penny stocks under $1 , and even some under 10 cents end up running thousands of percentage points. Fast-forward to right now, and countless stocks have come back down in a big way. But for those who found sympathy momentum and used it to their advantage, it was an early win in 2020.
[Read More] Esports Penny Stocks Surge On Tuesday & These 3 Lead The Charge
If you recall, back when Tesla did its Battery Day event, the market paid close attention to what CEO Elon Musk had to say. It wasn’t just a state of Tesla, but more of a state of the electric vehicle industry as a whole. He highlighted the potential need for more raw materials as production ramped up. With this, you’ll see that many of the electric vehicle penny stocks & even higher-priced stocks ended up rallying for a few weeks. The excitement died down a bit until we saw Joe Biden elected as the United States president.
This was where you see all sorts of green energy, alternative energy, EVs, and climate-related stocks begin to rally. Similar to the “virus trend,” many companies had little to no progress happening or at least announced. Yet traders still flocked to obscure names with popular keywords folded into these companies’ “About” sections.
Penny Stocks Jumping From Sympathy Trends Carry Higher Risk
Above I outlines a few of the bigger examples that we’ve seen over the last year. More recently, however, there’s another type of “sympathy” that involves technical aspects of the market. The Reddit penny stocks that’ve become infamous at this point kicked off the retail revolution in the stock market. GameStop ( NYSE: GME ) lead the charge, which triggered a flight to stocks with high short interest. It was at this point we saw traders paying attention to more than just industry or sector trends. Now the technical trade was in play.
When it comes to these sympathy trends, something to keep in mind is that there’s more risk involved than just general market risk. Since many companies tend to move “because of” another company’s developments, you’ve got to consider what happens next once the hype dies down.
As we saw, many of the Reddit penny stocks crumbled shortly after the big move. We also saw plenty of coronavirus and green energy penny stocks plummet since there wasn’t anything fundamentally different to suggest more potential in the stock. Just remember that nobody goes broke taking a profit. So if you find yourself putting a list of penny stocks together because of sympathy momentum, keep the risk side of the equation in mind.
Esports & Entertainment Penny Stocks Are Surging In March
This leads me to the latest trend that we’re seeing on a smaller scale. I say this because the number of penny stocks with direct or even partial exposure to Esports is less than the number of companies involved with vaccines or even green energy. Nevertheless, the trend has emerged and there are some names grabbing attention. Will they be the best penny stocks to buy right now or will this trend begin fading?
Liquid Media Group has been relatively quiet this year. However, early in 2021, the company began making adjustments to its management. A New CEO, Ronald Thomson, was appointed in January tasked with building upon Liquid’s entertainment business. Also, for those of you Mighty Ducks fans, the company’s Chairman is actor/producer Joshua Jackson (Charlie Conway).
In any event, Liquid made headlines this week with one of the most recognizable names in gaming and entertainment, Atari. The company’s SlipStream video-on-demand platform will be made available for download on Atari’s VCS PC/console hybrid. This is a modern gaming and video computer system, which blends consoles and PCs, delivering interactive entertainment.
[Read More] Making A List Of Penny Stocks? 5 Active Names To Watch This Week
So, while Liquid isn’t necessarily getting into esports or gaming directly, it does place them in front of an audience likely to be interested. Coincidentally enough, the VCS system is available for preorder on the Atari site and at GameStop.com.
#2: Allied Esports Entertainment Inc.
Allied, on the other hand, is more immersed in the esports space. In fact, the company had recently renewed its flagship property, the HyperX Esports Arena Las Vegas. I will say that AESE could be a beneficiary of sympathy momentum right now, and I’ll explain why. The company sold off one of its larger assets, the WPT poker brand. Its reasoning was to focus on strategic alternatives.
When I hear “strategic alternatives,” I think of companies looking to pivot. Allied has already tapped a strategic advisor, Lake Street Capital Markets, to help with this plan. The company even said that it would entertain a potential sale of its esports business. Ultimately, it looks like Allied’s goal is to become an entertainment holding company. No new updates have come out since then.
But we can see a clear example of sympathy sentiment driving momentum starting last week. Citron Research reported that GameStop should explore a purchase of Esports Entertainment Group ( NASDAQ: GMBL ) to pivot its business. This news acted as the catalyst and saw retail traders searching for companies with a similar business.
#3: Monaker Group Inc.
Monaker is a bit more obscure of an esports company. Rather, it could fall under the “entertainment” umbrella after the last few announcements it has made. Initially focused on the leisure space, some could’ve qualified this as a travel stock.
However, news from January puts this company right in the model of gaming. Monaker entered into an agreement that is subject to shareholder approval wherein it would acquire HotPlay Enterprise. HotPlay is an in-game advertising company.
The plan with this acquisition is to bring in the AdTech company and simultaneously “transform” into NextPlay Technologies, which will focus on products for video gaming and travel verticals. There could also be a tie-in for blockchain solutions, according to the company. While the market awaits the outcome of the shareholder vote, MKGI stock has seen some momentum building as it relates to a jump in entertainment and esports penny stocks.
#4: Blue Hat Interactive Entertainment Technology
Finally, Blue Hat Interactive develops augmented reality interactive entertainment games. It also produces toys and educational materials in China. Obviously, education technology has become a centerpiece of the global pandemic. Schools conducting virtual learning and even businesses relying on communications technology to advance on-the-job training have placed a spotlight on related companies.
[Read More] Uranium Penny Stocks, Should They Be On Your Watch List In 2021?
Blue had has been closing deals and gathering IP for use in things like social media. Everything from licensing brands to acquiring companies has boosted interest in the company. Its most recently closed purchase was that of a Chinese mobile game developer and distributor, Csfctech Co., Ltd.
“Over a longer period, this combination presents an incredible opportunity for Blue Hat to drive sales through an expanded interactive gaming portfolio, increased avenues for global distribution and increased brand recognition.”
Xiaodong Chen, CEO of Blue Hat
The wave of cannabis legislation reform sweeping across the United States has reached Pennsylvania, and the Commonwealth may very well be the next state to legalize cannabis. A new bipartisan bill introduced to the Pennsylvania legislature last week by state Senators Dan Laughlin and Sharif Street seeks to legalize marijuana, allowing individuals aged 21 and over to purchase and consume marijuana. The new bipartisan bill would also expunge the records of people with previous cannabis-related, nonviolent offenses.
Unlike the state’s medical cannabis market, which has just a few growers due to limited licenses, licenses for recreational cannabis growers would be widely available. Additionally, medical dispensaries that are currently selling medical cannabis would be allowed to sell marijuana for adult use. Although there have been attempts to pass cannabis legislation in the past, they have been unsuccessful in the Republican-controlled legislature. However, this new bill has a greater chance of success compared to past efforts because this is the first time legislation is being backed by a Republican.
Senator Laughlin notes that while he and Senator Street belong to different political parties, they have joined hands to ensure the state has a cannabis market that is based on safety as well as social equity. Speaking on Twitter, he said the new bipartisan bill would ensure legalization in Pennsylvania is done right. Street has been a vocal supporter of cannabis legalization in the state, going as far as helping people to register for medical marijuana cards.
In 2019, he co-sponsored a cannabis legalization bill with Senator Daylin Leach that would have legalized recreational cannabis, expunged prior nonviolent, cannabis-related convictions automatically and allowed home delivery. Unfortunately, the legislation didn’t make it past the committee stage. He later appeared in a news conference in September 2020 with Governor Tom Wolf who said the state needed to legalize recreational cannabis to help the thousands of Pennsylvanians in the criminal justice system as well as to raise revenue at a time when state coffers are running dry.
In a statement, Street said that he and Laughlin in collaboration with stakeholders and key community groups had developed a bill to legalize adult-use cannabis in Pennsylvania. On Twitter, he noted that Blacks and Latinos are four to five times more likely to be impacted by marijuana use, and they were committed to social justice reform. On top of changing the lives of thousands of Pennsylvanians with prior cannabis convictions for the better, legalization would also earn the state more than $400 million in revenue annually.
As discussions continue on the legalization of cannabis in different jurisdictions, many companies are recording success in the market for nonintoxicating cannabis products. For instance, The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) has distinguished itself as a supplier of various CBD-infused products (salves and lotions, for example) by adopting a model that ensures that a parking house or warehouse is within 600 miles from nearly the entire population of the United States.
NOTE TO INVESTORS: The latest news and updates relating to The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) are available in the company’s newsroom at http://cnw.fm/WTER
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
